Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Terazosin Repurposing Study in ALS (TRUST)

Terazosin RepUrposing STudy in ALS (TRUST) is a single-centre, interventional, open-label, non-randomised, non-controlled proof of concept study, funded by the My Name’5 Doddie Foundation, to assess the neuroprotective effects of terazosin in patients with ALS.

TRUST is managed by Dr Elizabeth Gray (elizabeth.gray@ndcn.ox.ac.uk) in collaboration with the Oxford Clinical Trials Research Unit (OCTRU).

Our collaborator Professor Tom Gillingwater (University of Edinburgh) and his team attend our TRUST trial management group meetings on a monthly basis to discuss trial progress.

Recruitment is well advanced and we will continue until we reach our target which is currently scheduled to be in March 2024. Results will be available later in the year.